This core resulted from the reorganization and restructuring of two of our previous cores, i.e. the Cell Biology and Molecular Biology Cores. The latter had evolved significantly over the years in response to the shifting needs of our investigators. However, in January 2007, Dr. Shouying Du, the Core's full-time Research Associate left to pursue her clinical training. This provided an opportunity to reassess how to best support the on-going and future needs of the Center members, by obtaining their input. As to the Cell Biology Core, while the instrumentation base and services of its Subcellular-Organelle and Equipment Subcore had kept expanding, the need for purified organelle and membrane preparations had declined substantially, due to shifting needs of our investigators. The combination of these two developments provided us with the opportunity to review and reassess the needs of our investigators for the resources and services offered through these two entities and to restructure them into a new and expanded core under the present title. The Center's external Advisory Board and the internal Executive Committee were presented with our needs and rationale for restructuring and approved the establishment of the present core starting with grant year 3 (i.e. 3/1/07). Thus, the core pooled the already extensive and critically needed/used instrumentation base and the menu of analytical services (multi-detection HPLC) of the Subcellular-Organelle and Equipment Subcore with that of the previous Molecular Biology Core into a new and expanded Central Core (see details below). Furthermore, to the analytical resources and services offered by the expanded base above, additional state-ofthe- art analytical and metabolic resources and services were added through two newly formed subcores, i.e.: a Mass Spectrometry-Based Proteomics Subcore (Proteomic Subcore) and a Small Molecule Identification/Mass Spectrometry Subcore (Small Molecule Subcore). The detailed descriptions of the Central Core and each of the two Subcores are presented in their respective sections below. In the process, support for the USC Institute of Genetic Medicine Microarray Facility, a Subcore of the prior Molecular Biology Core, was eliminated, along with the costs to the Center grant associated with these services. This was done in part due to the reduced interest for this service. However, microarray services will otherwise remain available to the Center Members who may need them. The following faculty were appointed to direct the new core and its subcores: Murad Ookhtens, Ph.D., Central Core Director (5% effort) Ebrahim Zandi, Ph.D., Mass Spectrometry-Based Proteomics Subcore Director (10% effort) Stan Louie, Pharm. D., Small Molecule Identification/Mass Spectrometry Subcore Director (5% effort) Besides directing the Central Core, Dr. Ookhtens will co-ordinate and work closely with the two subcore directors to insure that their services remain responsive to the Center's objectives and needs. Drs. Zandi and Louie will each direct their respective subcores and will communicate with Dr. Ookhtens regarding their usage and reporting activities. As in the past, the core and subcore directors will be required to report their respective performances during the Executive Committee meetings. In addition to the above. Dr. Andrew Stolz, Director of the previous Molecular Biology Core, will continue serving at no cost to the Center, as an advisor to investigators who need the use of some of the resources and instruments that were previously under the Molecular Biology Core. He will thus assist Dr. Ookhtens for the optimum utilization of these, as well as identify essential future equipment upgrades and acquisitions. The Central Core and the Mass Spectrometry-Based Proteomics Subcore are located in the Hoffman Medical Research (HMR) building, with the Small Molecule Identification/Mass Spectrometry Subcore located next door in the School of Pharmacy building.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK048522-20
Application #
8616057
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
20
Fiscal Year
2014
Total Cost
$242,471
Indirect Cost
$92,896
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Chang, Huiyi H; Yeh, Jih-Chao; Ichiyama, Ronaldo M et al. (2018) Mapping and neuromodulation of lower urinary tract function using spinal cord stimulation in female rats. Exp Neurol 305:26-32
Chen, Chien-Yu; Chen, Jingyu; He, Lina et al. (2018) PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne) 9:338
Nakamura, Brooke N; Glazier, Alison; Kattah, Michael G et al. (2018) A20 regulates canonical wnt-signaling through an interaction with RIPK4. PLoS One 13:e0195893
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Wu, Raymond; Murali, Ramachandran; Kabe, Yasuaki et al. (2018) Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology 68:1726-1740
Ogasawara, Noriko; Poposki, Julie A; Klingler, Aiko I et al. (2018) IL-10, TGF-?, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. J Allergy Clin Immunol 141:1147-1151.e8
Edman, Maria C; Janga, Srikanth R; Meng, Zhen et al. (2018) Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients. Sci Rep 8:11044
Baulies, Anna; Montero, Joan; Matías, Nuria et al. (2018) The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading. Redox Biol 14:164-177
Ju, Yaping; Janga, Srikanth Reddy; Klinngam, Wannita et al. (2018) NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis. Exp Eye Res 176:243-251
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184

Showing the most recent 10 out of 449 publications